Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope

Nori Nakayashiki, Minako Oshima, Philip R. Deitiker, Tetsuo Ashizawa, M. Zouhair Atassi

Research output: Contribution to journalArticle

13 Scopus citations

Abstract

We have prepared monoclonal antibodies (mAbs) against an antigen-binding region of I-A, region 62-76 of I-Aβb, which is involved in the T-cell participation in the pathogenesis of EAMG. The mAbs reacted with its parent molecules and inhibited the proliferation of disease-related T-cells. Passive transfer of these mAbs suppressed the occurrence of clinical EAMG, which was accompanied by decreased T-cell and Ab responses to tAChR. The results indicated that blocking the function of disease-related MHC by targeting a disease-associated region on MHC molecules could be an effective, straightforward and feasible strategy for immunointervention in MG. Copyright (C) 2000 Elsevier Science B.V.

Original languageEnglish (US)
Pages (from-to)131-144
Number of pages14
JournalJournal of Neuroimmunology
Volume105
Issue number2
DOIs
StatePublished - Jun 26 2000

Keywords

  • Antibodies
  • Antigen presentation
  • Autoimmunity
  • Immunotherapy
  • MHC

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Suppression of experimental myasthenia gravis by monoclonal antibodies against MHC peptide region involved in presentation of a pathogenic T-cell epitope'. Together they form a unique fingerprint.

Cite this